Skip to main content

Topic

Drug Labeling

96 published works

  1. Supreme Court Update

    Wyeth v. Levine (06-1249), Summers v. Earth Island Institute (07-463), Negusie v. Holder (07-499) and order list

    By Kim Rinehart

    The Court issued three decisions and an Order List this week. The ruling garnering all the press came in Wyeth v. Levine (06-1249), which is being hailed as a victory…

  2. Drug & Device Law

    Preemption Highlights

    By Bexis

    Bexis attended the recent Rolling Stones concert in Philadelphia – the first time he’d seen them live since 1975.  The highlights:  while they’re really old (Jagger just turned 76), they…

  3. The Right Coast

    Sleeping pills, like Sonata, Ambien, need new warning labels, FDA says

    By Thomas A. Smith

    Among the 66 cases, 20 were fatal. The deaths were caused by carbon monoxide poisoning, drowning, falls, hypothermia, car accidents with the patient driving and apparent suicide, the FDA said.The 46 non-fatal…

  4. Drug & Device Law

    Government Urges Reversal of Third Circuit Fosamax Decision

    By Stephen McConnell

    We would be hard pressed to think of a recent judicial decision we have blasted as hard or often as the Third Circuit’s Fosamax opinion.  We deemed it the worst…

  5. Drug & Device Law

    Sixth Circuit Finds Failure to Distribute Medication Guide Claim Preempted

    By Michelle Yeary

    Being that it was the Sixth Circuit that allowed a failure-to-update claim to proceed against a generic manufacturer, when we got the recent decision in McDaniel v. Upsher-Smith Labs, 2018…

  6. Administrative and Regulatory

    Recent State Court Decisions and FDA Inaction Leave Brand Name Manufacturers Uncertain About Liability for Updating Safety Labeling: The Impact of the “Sameness” Standard

    By Bradley S. Davidsen, Tristan A. Potter, Chelsea E. Ott

    Two cases decided over the last three months have added California[1] and Massachusetts[2] to the list of minority states that hold brand name manufacturers of drugs (“Brand Manufacturers”) liable under…

  7. Drug & Device Law

    “A” Is For Preemption

    By Steven Boranian

    The Seventh Circuit taught us recently that the letter “A” is a powerful thing. Of course, we already knew that a well-placed A can convert the ordinary (“typical”) into the…

  8. Drug & Device Law

    Just What the Doctor Ordered: Package Insert Does not Establish Standard of Medical Care

    By Stephen McConnell

    Like most Americans, we like our doctor.  We like doctors in general.  We are not looking to start another song battle with our friends over at the Abnormal Use blog,…

  9. Business and Commercial

    Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims

    By Bradley Graveline

    After several years of delay, FDA announced this summer that it expects to publish new rules in April 2017 that will permit generic drug companies to make unilateral changes to…

  10. Health Care and Life Sciences

    New FDA Draft Guidance Shows Limited Compromise with Brand and Generic Drug Manufacturers

    By Bradley S. Davidsen

    The Food and Drug Administration (FDA) issued a draft guidance (Draft Guidance) on July 11, 2016 that allows some generic drug manufacturers holding an Abbreviated New Drug Application (ANDA) to…